DeepMed Research

BeiGene Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public

Established: 2010-01-01

Employees: 10K

Market Cap: $22.1B

Website: http://www.beigene.com

Clinical Trials

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3

Not yet recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: BGB-16673
Drug: Pirtobrutinib

First Posted Date: 2025-05-15

Last Posted Date: 2025-05-15

Lead Sponsor: BeiGene

Target Recruit Count: 500

Registration Number: NCT06973187

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Phase 3

Not yet recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: BGB-16673
Drug: Bendamustine
Drug: Rituximab
Drug: Methylprednisolone

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-20

Lead Sponsor: BeiGene

Target Recruit Count: 150

Registration Number: NCT06970743

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Phase 3

Not yet recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Sonrotoclax
Drug: Obinutuzumab
Drug: Rituximab
Drug: Venetoclax

First Posted Date: 2025-04-24

Last Posted Date: 2025-04-24

Lead Sponsor: BeiGene

Target Recruit Count: 630

Registration Number: NCT06943872

Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: BGB-16673
Drug: Phenytoin
Drug: Itraconazole

First Posted Date: 2025-04-02

Last Posted Date: 2025-05-01

Lead Sponsor: BeiGene

Target Recruit Count: 30

Registration Number: NCT06906809

Locations: 🇺🇸
Fortrea Clinical Research Unit Inc, Madison, Wisconsin, United States

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Phase 3

Recruiting

Conditions: CLL
Chronic Lymphocytic Leukemia

Interventions: Drug: BGB-16673
Drug: Bendamustine
Drug: Idelalisib
Drug: Rituximab
Drug: Venetoclax

First Posted Date: 2025-02-26

Last Posted Date: 2025-05-16

Lead Sponsor: BeiGene

Target Recruit Count: 250

Registration Number: NCT06846671

Locations: 🇳🇿
North Shore Hospital, Auckland, New Zealand
🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States
🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

and more 96 locations

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Metastatic Solid Tumor

Interventions: Drug: BGB-B455

First Posted Date: 2025-01-31

Last Posted Date: 2025-05-09

Lead Sponsor: BeiGene

Target Recruit Count: 80

Registration Number: NCT06803680

Locations: 🇺🇸
Ut Health San Antonio Mays Cancer Center, San Antonio, Texas, United States
🇺🇸
Next Oncology, San Antonio, Texas, United States
🇺🇸
Adventhealth, Celebration, Florida, United States

and more 12 locations

A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [14C]-BGB-16673

First Posted Date: 2025-01-15

Last Posted Date: 2025-05-01

Lead Sponsor: BeiGene

Target Recruit Count: 8

Registration Number: NCT06776679

Locations: 🇺🇸
Fortrea Clinical Research Unit Inc, Madison, Wisconsin, United States

A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: BGB-43395

First Posted Date: 2025-01-07

Last Posted Date: 2025-04-11

Lead Sponsor: BeiGene

Target Recruit Count: 48

Registration Number: NCT06761898

Locations: 🇺🇸
Fortrea Cru, Daytone Beach, Daytona Beach, Florida, United States

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Phase 1

Recruiting

Conditions: Hormone-receptor-positive Breast Cancer
HER2-negative Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: BGB-21447
Drug: Fulvestrant
Drug: BGB-43395

First Posted Date: 2025-01-03

Last Posted Date: 2025-05-09

Lead Sponsor: BeiGene

Target Recruit Count: 92

Registration Number: NCT06756932

Locations: 🇺🇸
Hoag Memorial Presbyterian, Newport Beach, California, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States

and more 12 locations

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma

Phase 3

Recruiting

Conditions: Mantle Cell Lymphoma
B Cell Lymphoma

Interventions: Drug: Sonrotoclax
Drug: Zanubrutinib
Drug: Placebo

First Posted Date: 2024-12-19

Last Posted Date: 2025-05-09

Lead Sponsor: BeiGene

Target Recruit Count: 300

Registration Number: NCT06742996

Locations: 🇵🇱
Uniwersytecki Szpital Kliniczny Nr W Lublinie, Lublin, Poland
🇺🇸
University of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States

and more 143 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy